Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

IT: Canapar welcomes RAMM Pharma, closes $6,427,000 financing

Canapar and RAMM Pharma have entered into a strategic partnership, combining Canapar’s hemp-derived cannabidiol extraction expertise with RAMM’s leadership in cannabis-derived pharmaceutical and cosmeceutical products. As part of the strategic partnership, RAMM has acquired Canopy Rivers’ 49% ownership interest in Canapar. This investment is expected to immediately enhance both RAMM and Canapar’s ability to capitalize on the rapidly expanding European and South American hemp-derived CBD markets.

"We are very excited to welcome RAMM as our newest partner,” said Sergio Martines, CEO, Canapar. “Together, we are a powerful team that can cross-leverage our respective expertise, product portfolios and established presence in a growing number of international markets. We are proud of this partnership and believe that it will further entrench Canapar as the largest CBD extraction company in Europe.”

“This investment will accelerate Canapar’s ability to establish itself as a leader in the European market while providing RAMM with strategic benefits, including exposure to the EU market,” said Jack Burnett, CEO, RAMM.

On January 4th, 2021, Canapar closed a convertible debenture valued CA$6,427,000 for the completion of its extraction facility.

For more information:
Canapar
C.da Piancatella, Zona Ind. IV fase
97100 Ragusa (RG), Italy
+39 0932 1836095
canapar.com   

Publication date: